|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, November 12, 2009 ) New York, NY - MabCure has invented a brilliant new way to spot and successfully “mark” cancer cells at their earliest stage, so that they literally stand out, and can then be eliminated. The opportunity is so immense, some analysts predict the market for this type of therapy and approach can reach $22 billion per year, with an annual growth rate of 30%.
The Company has developed a series of antibodies that can mark cancer cells at their earliest stages. I’m going to assume that your knowledge of medical terms equals mine—you need things explained so you can can understand them. An antibody is simply a protein molecule that attaches itself to a cancer cell so the cancer cell can then be found. Think of the antibody as a friend planting a bright orange “flag” in the target so it can be destroyed using existing treatments. This extremely specific, safe, no-side-effects targeting of cancer cells has huge benefits.
Results Beyond Impressive
A Study of 13 People Found What No Other Test Could Detect
MabCure did a pilot study looking at 13 patients with ovarian cancer—half of which went through chemotherapy. They examined the blood of these patients with the antibodies they discovered. The objective was to see if their antibodies could successfully find and “mark” any remaining cancer cells in the blood. However, according to the standard existing detection methods, these patients were in remission since they found no cancer cells left in their systems. The result stunned even skeptics. MabCure’s antibody detected cancer cells remaining in the blood of all 13 patients. Every other test had missed them. This proves that their antibody was highly sensitive, extremely specific and accurate.
Another Study Confirmed Their Theory - 100% Accurate
MabCure then tested 30 patients with melanoma. One of their antibodies, designed specifically to find these particular cells, did so in 30 out of 30 patients. It correctly identified 100% of the different melanoma cells. They did what no other medical technology in the world could do.
Doctors are helpless when it comes to the very early detection of cancer. Using current methods, by the time they recognize the presence of cancer, depending on the kind it is, it is often too late. But when detected early, the survival rate skyrockets. This illness is only destructive if it progresses. The National Cancer Institute says, “Unfortunately, many cancers have no symptoms at early stages and are not detected until it is too late.”
MabCure is delivering on this need. The technology MabCure developed spots these problems earlier than an technology doctors have at their disposal today.
Becoming a Major Player in a Multi-Billion Dollar Market
MabCure Can Become a Major Player In a Market ThatÂ’s Estimated to Hit $22 Billion in Sales by 2010.
Just two years ago, the therapeutic antibodies market enjoyed industry-wide sales of $7.3 billion. This market is expected to grow by 30% annually and reach $22 billion by 2010. Cancer dominates this market because the rewards of success dwarf most other ventures on the planet. Chemistry World magazine correctly says, “Cancer is a huge market.” It is an unfortunate fact, but a fact nonetheless.
Three-Step Marketing Plan
Being a small company, MabCure is marketing their invention in a very smart way. There are three broad ways to maximize revenue potential. The first is using this technology in diagnosing or screening for the three illnesses. This is where there is, naturally, instant overnight demand. Second is in the imaging of the illnesses. This simply means a physical picture a doctor looks at to analyze your condition. They can now see the illness. This is extremely useful by doctors. Third, is in developing new drugs that can defeat this illness in a quicker, more efficient way. “The market potential of these new drugs is in the multi-billion dollar range,” says MabCure.
Antibodies For Three Cancers
Ovarian Cancer is Almost Always Detected When It’s Too Late - Forbes magazine Calls This, “Scandalous” and They’re Right.
Last year 22,430 new cases were diagnosed and 15,280 women died from this illness. 1 in 7 women during their lifetime will get it. The biggest problem with this illness is late diagnosis. Most are found to have it when doctors can’t stop it. Tragically, it’s one of the easiest to halt—IF you detect it in advance. Until now, thanks to MabCure, there has been NO diagnostic test for ovarian cancer. Between 61 and 100 million women pay $25 to have a pap smear to detect illness, a highly unreliable test. This adds up to $1.5 billion a year spent on ineffective healthcare measures, a market MabCure could capture with an effective detection method.
Prostate Cancer Touched 218,890 People In 2008. PSA Tests are Shockingly Bad - Even the Inventor of the Test Admits It!
Prostate cancer is another senseless way to lose your health. Catch this one early and it too is no problem. In 2008, 218,890 cases were diagnosed. Sadly, 27,050 perished from it. It’s the second leading cause of death among men. According to the organization Cancer Facts, “Every man over the age of 45 is at risk for it…” Most men rely on the famous PSA test. That’s a major mistake because it is so incredibly unreliable. Medical Research News reports, “The PSA test is now all but useless for predicting prostate cancer risk.” Even the doctor who invented it, Dr. Thomas Stamey now says that it may be useless in detecting prostate cancer.
According to The American Cancer Society, itÂ’s estimated that more than 40 million PSA tests are performed worldwide each year. Since the cost per PSA test is $40 to $80, the world market for these tests ranges from $1.6 to $3.2 billion annually. Another huge market segment MabCure could capture with a reliable testing method based on their breakthrough discovery.
Melanoma Has a 99% Survival Rate IF ItÂ’s Found Early - 8,110 People Should Have Been Saved Last Year.
Melanoma is the most serious form of skin cancer. It suddenly appears without warning. The American Academy of Dermatology says, “melanoma is rising at an alarming rate.” One American passes away from it every hour. Unfortunately, it’s the most common form of cancer in the country. As the Mayo Clinic says, “If detected early, melanoma has a 99% survival rate…” Last year, 108,230 cases were diagnosed.
MabCureÂ’s strategy is to first concentrate on deadly, fast-growing cancers where demand is instant, huge and growing. ItÂ’s a sound, realistic business objective.
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately. Anyone not wishing to receive future Keros Capital Investor Reports should email us at opt-out@keroscapital.com
MabCure Inc.
Jim Mav
908-464-1747
jimmav@keroscapital.com 
Source: EmailWire.com
|
|
|
|
